Candida auris: What We Need to Know in Healthcare Settings
Purpose of review
Candida auris is an emerging pathogen characterized for its difficult identification, rapid nosocomial spread, and limited treatment options. Data is currently limited; however, this will change as the pathogen’s prevalence increases. The goal of this review is to provide a concise summary of the available data to manage a possible C. auris infection.
Candida auris has been rapidly spreading globally and has been evading popular identification methods with MALDI-TOF being the only successful modality as long as the “research use only” database is used. Echinocandins are the treatment of choice; however, all isolates should have susceptibilities performed as there have been reports of resistance to all antifungal classes. Several hospital outbreaks have occurred; thus, all patients should be isolated with appropriate terminal cleaning.
Atypical or suspicious Candida isolates should be identified by MALDI-TOF. Most Candida auris strains are resistant to azoles; therefore, the suggested empirical treatment is an echinocandin. Echinocandin-resistant strains have been reported, and in those cases, a polyene is preferred. Strict contact precautions are recommended while in the hospital due to high levels of nosocomial transmission.
KeywordsCandida auris Epidemiology Candidemia Infection control Nosocomial transmission
Compliance with ethical standards
Conflict of interest
Cima Nowbakht declares that she has no conflict of interest. Luis Ostrosky-Zeichner has received research grants and/or consulting honoraria and lecture fees from Merck, Pfizer, Astellas, Scynexis, and Cidara.
Human and animal rights and informed consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53:41–4. https://doi.org/10.1111/j.1348-0421.2008.00083.x.CrossRefPubMedGoogle Scholar
- 5.Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, Kemble SK, Pacilli M, Black SR, Landon E, Ridgway J, Palmore TN, Zelzany A, Adams EH, Quinn M, Chaturvedi S, Greenko J, Fernandez R, Southwick K, Furuya EY, Calfee DP, Hamula C, Patel G, Barrett P, Lafaro P, Berkow EL, Moulton-Meissner H, Noble-Wang J, Fagan RP, Jackson BR, Lockhart SR, Litvintseva AP, Chiller TM. 2016. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus—United States, May 2013–August 2016. MMWR Morb Mortal Wkly Rep 65:1234–1237. https://doi.org/10.15585/mmwr.mm6544e1.
- 6.Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, Lopes Colombo A, Calvo B, Cuomo CA, Desjardins CA, Berkow EL, Castanheira M, Magobo REE, Jabeen K, Asghar RJ, Meis JF, Jackson B, Chiller T, Litvintseva AP. 2017. Simultaneous emergence of multidrug resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 64:134–140. https://doi.org/10.1093/cid/ciw691.
- 9.• Mizusawa M, Miller H, Green R, Lee R, Durante M, Perkins R, et al. Can multidrug resistant Candida auris be reliably identified in clinical microbiology laboratories? J Clin Microbiol. 2016;55:638–40. https://doi.org/10.1128/JCM.02202-16. This study presented a detailed evaluation of the challenges that widely used biochemical devices were routinely misidentifying C. auris CrossRefPubMedGoogle Scholar
- 10.Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization–time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol. 2015;53:1823–30. https://doi.org/10.1128/JCM.00367-15.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Tsay S, et al. Approach to the investigation and management of patients with Candida auris, an emerging multidrug-resistant yeast. Clin Infect Dis. 2017 Aug;17Google Scholar
- 13.Kumar A, Sachu A, Mohan K, Vinod V, Dinesh K, Karim S. Simple low cost differentiation of Candida auris from Candida haemulonii complex using CHROMagar Candida medium supplemented with Pal’s medium. Rev. Iberoam Micol. 2017;34:109–11. https://doi.org/10.1016/j.riam.2016.11.004.CrossRefPubMedGoogle Scholar
- 15.Girard V, Mailler S, Chetry M, Vidal C, Durand G, van Belkum A, et al. Identification and typing of the emerging pathogen Candida auris by matrix-assisted laser desorption ionization time of flight mass spectrometry. Mycoses. 2016;59:535–8. https://doi.org/10.1111/myc.12519.CrossRefPubMedGoogle Scholar
- 16.Arendrup MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A. Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob Agents Chemother. 2017;61:e00485–17. https://doi.org/10.1128/AAC.00485-17.PubMedPubMedCentralGoogle Scholar
- 17.Fakhim H, Chowdhary A, Prakash A, Vaezi A, Dannaoui E, Meis JF, et al. In vitro interactions of echinocandins with triazoles against multidrug-resistant Candida auris. Antimicrob Agents Chemother. 2017; https://doi.org/10.1128/AAC.01056-17.
- 22.European Centre for Disease Prevention and Control. Candida auris in healthcare settings—Europe. Stockholm, Sweden: European Centre for Disease Prevention and Control; 2016.Google Scholar
- 23.England PH. Guidance for the laboratory investigation, management and infection prevention and control for cases of Candida auris. United Kingdom: Public Health England; 2017.Google Scholar
- 24.Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, et al. Survival, persistence, and isolation of the emerging multidrug resistant pathogenic yeast Candida auris on a plastic healthcare surface. J Clin Microbiol. 2017;55:2996–3005. https://doi.org/10.1128/JCM.00921-17.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.•• Abdolrasouli A, Armstrong-James D, Ryan L, Schelenz S. In vitro efficacy of disinfectants utilized for skin decolonisation and environmental decontamination during a hospital outbreak with Candida auris. Mycoses. 2017;60:758–63. https://doi.org/10.1111/myc.12699. This study provides in vitro data on several current methods to disinfectant hospital environments and colonized patients CrossRefPubMedGoogle Scholar
- 26.Shackleton J, Schelenz S, Rochon M, Hall A, Ryan L, Cervera-Jackson R. 2016. The impact of environmental decontamination in a Candida auris outbreak. J Hosp Infect 94(Suppl 1):S24 –S134. https://doi.org/10.1016/S0195-6701(16)30516-3.
- 27.Piedrahita CT, Cadnum JL, Jencson AL, Shaikh AA, Ghannoum MA, Donskey CJ. Environmental surfaces in healthcare facilities are a potential source for transmission of Candida auris and other candida species. Infect Control Hosp Epidemiol. 2017;38:1107–9. https://doi.org/10.1017/ice.2017.127.CrossRefPubMedGoogle Scholar
- 28.Tsay S, Welsh RM, Adams EH, Chow NA, Gade L, Berkow EL, Poirot E, Lutterloh E, Quinn M, Chaturvedi S, Kerins J, Black SR, Kemble SK, Barrett PM, Barton K, Shannon DJ, Bradley K, Lockhart SR, Litvintseva AP, Moulton-Meissner H, Shugart A, Kallen A, Vallabhaneni S, Chiller TM, Jackson BR. 2017. Notes from the field: ongoing transmission of Candida auris in health care facilities—United States, June 2016–May 2017. MMWR Morb Mortal Wkly Rep 66:514–515. https://doi.org/10.15585/mmwr.mm6619a7.
- 29.Moore G, Schelenz S, Borman AM, Johnson EM, Brown CS. The yeasticidal activity of chemical disinfectants and antiseptics against Candida auris. J Hosp Infect. 2017; https://doi.org/10.1016/j.jhin.2017.08.019.
- 31.Sarma S, Kumar N, Sharma S, Govil D, Ali T, Mehta Y, Rattan A. 2013. Candidemia caused by amphotericin B and fluconazole resistant Candida auris. Indian J Med Microbiol 31:90–91. https://doi.org/10.4103/0255-0857.108746.
- 33.Madder H, Moir I, Moroney R, Butcher L, Newnham R, Sunderland M, Clarke T, Foster D, Hoffman P, Moore G, Brown CS, Jeffery KJM. 2017. Multiuse patient monitoring equipment as a risk factor for acquisition of Candida auris. bioRxiv 149,054. https://doi.org/10.1101/149054.